The National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium 2 6 (CPTAC) has established a two-dimensional liquid chromatography-tandem mass 2 7 spectrometry (2DLC-MS/MS) workflow using isobaric tagging to compare protein 2 8
abundance across samples. The workflow has been used for large-scale clinical 2 9
proteomic studies with deep proteomic coverage within and outside of CPTAC. SWATH-3 0
MS, an instance of data-independent acquisition (DIA) proteomic methods, was recently 3 1 developed as an alternate proteomic approach. In this study, we analyzed remaining 3 2 aliquots of peptides using SWATH-MS from the original retrospective TCGA samples 3 3 generated for the CPTAC ovarian cancer proteogenomic study (Zhang et al., 2016) . The 3 4
SWATH-MS results indicated that both methods confidently identified differentially 3 5
expressed proteins in enriched pathways associated with the robust Mesenchymal 3 6
subtype of high-grade serous ovarian cancer (HGSOC) and the homologous 3 7
recombination deficient tumors also present in the original study. The results 3 8 demonstrated that SWATH/DIA-MS presents a promising complementary or orthogonal 3 9
alternative to the CPTAC harmonized proteomic method, with the advantages of simpler, 4 0 faster, and cheaper workflows, as well as lower sample consumption. However, the 4 1 SWATH/DIA-MS workflow resulted in shallower proteome coverage. Overall, we 4 2 concluded that both analytical methods are suitable to characterize clinical samples 4 3 such as in the high-grade serous ovarian cancer study, providing proteomic workflow 4 4
alternatives for cancer researchers depending on the specific goals and context of the 4 5 studies. 4 6 Introduction 4 8
Advances in sample preparation workflows, mass spectrometry instrumentation, and 4 9
data processing software have positioned proteomics to provide comprehensive insights 5 0 into complex biological processes at a level close to the underlying biochemical 5 1 mechanisms. Indeed, it is currently possible to routinely quantify >10,000 proteins in 5 2 human cell proteomes (Beck et al., 2011; Nagaraj et al., 2011) and human tissue 5 3
proteomes (Kim et al., 2014; Mertins et al., 2018; Wilhelm et al., 2014) using mass 5 4
spectrometry-based platforms. The workflows for many of these large-scale proteomic 5 5 studies entail extensive offline fractionation of the peptides generated from 5 6 enzymatically-digested proteins, followed by LC-MS/MS. Consequently, proteomic 5 7
analysis of large cohorts of clinical specimens (>100) requires several months for data 5 8 acquisition using the afore-mentioned workflows. Further, because each fraction 5 9
analyzed typically requires 1-5 microgram of total peptides, the required quantity of the 6 0 original tissue sample is in the milligram level. Although more rapid proteomic workflows 6 1 have been developed (Anagnostopoulos et al., 2017; Hebert et al., 2014; Kulak et al., 6 2 2014; Richards et al., 2015) , they have not yet been deployed for large-scale clinical 6 3 proteomic studies. 6 4 6 5
Examples of large-scale clinical proteomic studies using the 2DLC-MS/MS workflow 6 6 described above include the NCI CPTAC studies. CPTAC was formed to accelerate the 6 7
understanding of the molecular basis of cancer through the application of large-scale 6 8 proteogenomic analyses. Several hundred tumor tissue specimens from breast, ovarian, 6 9
and colorectal cancer tissues previously analyzed by NCI's The Cancer Genome Atlas 7 0 (TCGA) have also been characterized using proteomics, informed by genomics, 7 1 resulting in the identification and quantification of proteins and phosphoproteins in 7 2 cancer-associated cell signaling pathways and networks (Mertins et al., 2016; Zhang et 7 3 al., 2014a; Zhang et al., 2016a) . These studies employed data-dependent acquisition 7 4 (DDA) mass spectrometry, a mode of MS/MS data collection wherein a fixed number of 7 5
precursor ions whose m/z values were recorded in a survey scan are selected for 7 6 fragmentation using a pre-determined set of rules (Mann et al., 2001) . DDA-based 7 7
proteomic workflows have undergone considerable optimization to improve the reliability 7 8 P a g e 4 o f 4 0 and reproducibility of the generated data in an effort to minimize the limitations due to 7 9
the stochastic nature of precursor ion selection and low sampling efficiency resulting in 8 0 missing values across data sets (Mertins et al., 2018; Revesz et al., 2018; Tabb et al., 8 1 2016; Zhou et al., 2017) . 8 2 8 3
A relatively newer method termed data-independent acquisition (DIA) mass 8 4 spectrometry has been gaining traction in large-scale proteomic studies (Vidova and 8 5
Spacil, 2017). DIA mass spectrometry is an alternative to DDA which allows all ions 8 6
within a selected mass range to be concurrently fragmented and analyzed by tandem 8 7 mass spectrometry. Sequential Window Acquisition of All Theoretical Mass Spectra 8 8
(SWATH-MS) is an example of a DIA acquisition method whose use in proteomic 8 9
studies has increased considerably within the past five years. The SWATH-MS method 9 0 acquires a complete and permanent digital fragment ion record for all detectable 9 1
precursor ions of a sample (Collins et al., 2013; Gillet et al., 2012; Liu et al., 2013) and 9 2
introduced an iterative, targeted search strategy that determines the presence and 9 3 quantity of tens of thousands of query peptides using reference fragment ion spectra for 9 4
the query peptides as prior information (Rost et al., 2014) . To support SWATH/DIA data 9 5 analysis, several software tools have been developed and benchmarked (Navarro et al., 9 6 2016). As with any analytical methodology that has potential widespread use, several 9 7 studies have been conducted to optimize and evaluate the performance of SWATH-MS 9 8 (Li et al., 2017b; Rardin et al., 2015) . In a multi-laboratory study including 11 sites 9 9
worldwide, SWATH-MS was shown to have a linear dynamic range exceeding 4 orders 1 0 0 of magnitude with an inter-laboratory CV of 22.0 ± 17.4% (Collins et al., 2017) , 1 0 1 demonstrating that SWATH-MS is a reproducible method for large-scale protein 1 0 2 quantification. 1 0 3 1 0 4
To assess the potential of SWATH-MS in addressing some of the common limitations of 1 0 5
DDA proteomic workflows, comparative analyses of SWATH-MS and DDA using 1 0 6
isobaric tags for relative and absolute quantitation (iTRAQ) have been conducted (Basak 1 0 7 et al., 2015; Bourassa et al., 2015; Zhang et al., 2014b) . Basak et al. concluded that 1 0 8
SWATH-MS and iTRAQ DDA are complementary techniques with a 60% overlap of the 1 0 9
high confidence quantifiable proteins identified by both methods using Saccharomyces 1 1 0 P a g e 5 o f 4 0 cerevisiae as a model system when incorporating offline peptide fractionation into the 1 1 1 LC-MS workflow (Basak et al., 2015) . In their study, Basak et al. incorporated first 1 1 2 dimension separation using strong cation exchange chromatography wherein the 1 1 3 peptides were fractionated into six fractions followed by second dimension separation 1 1 4
using reversed-phase chromatography prior to LC-MS analysis. 1 1 5 1 1 6
In the current study, we utilized SWATH-MS to analyze peptides from 103 HGSOC 1 1 7
tumors that were previously analyzed by iTRAQ DDA as part of the NCI CPTAC study 1 1 8
( Zhang et al., 2016a) . The iTRAQ DDA proteomic workflow resulted in the identification 1 1 9
of 8,597 proteins from these tumors using a 24-fraction peptide separation method, 1 2 0
whereas 2,914 proteins were quantified by SWATH-MS without peptide fractionation. 1 2 1
We compared the two proteomic workflows on the basis of cost, robustness, complexity, 1 2 2 ability to detect differential protein expression, and the elucidated biological information. 1 2 3
Our analysis demonstrated that despite the greater than 2-fold difference in the 1 2 4 analytical depth of iTRAQ DDA compared to SWATH-MS common differentially 1 2 5 expressed proteins in enriched pathways associated with the HGSOC Mesenchymal 1 2 6 subtype were identified by both workflows with 96% of the proteins quantified by 1 2 7
SWATH-MS also quantified by iTRAQ DDA. We also showed that tumor subtype 1 2 8 classification stability is sensitive to the number of samples that are analyzed. Lastly, our 1 2 9
results indicated a conservation of the homologous recombination deficiency (HRD)-1 3 0 associated enriched DNA repair and chromosome organization pathways in the iTRAQ 1 3 1 DDA and SWATH-MS data sets, thus indicating that some biological information for 1 3 2
HGSOC could be consistently extracted from either dataset. Proteomic measurements of clinically-annotated HGSOC previously characterized by 1 5 0 TCGA (Cancer Genome Atlas Research, 2011) were conducted using an iTRAQ DDA 1 5 1 workflow entailing stable isotope labeling, offline fractionation, and LC-MS/MS analysis 1 5 2 of each fraction (Zhang et al., 2016a) . A total of 103 of these tumors were used for the 1 5 3 current SWATH-MS analysis. An overview of the experimental design of our study is 1 5 4
shown in Figure 1 . 1 5 5 1 5 6
Protein was extracted from each tumor specimen followed by enzymatic digestion with 1 5 7
trypsin. For the iTRAQ DDA workflow, the resulting peptides were labeled with 4-plex 1 5 8 iTRAQ reagents followed by combination into analysis sets comprised of the peptides 1 5 9 from three tumors, each labeled with a distinct iTRAQ tag, and an iTRAQ-labeled 1 6 0 reference pool comprised of the peptides from most of the tumors. Each analysis set 1 6 1 was subjected to offline fractionation into 24 concatenated fractions, and the fractions 1 6 2 from each analytical set were sequentially analyzed using a DDA method on an LTQ-1 6 3
Orbitrap Velos mass spectrometer. An unfractionated aliquot of each analytical set was 1 6 4 also analyzed by DDA-MS without fractionation. In comparison, the SWATH-MS 1 6 5 workflow did not require stable isotope labeling. However, for the purpose of generating 1 6 6 a spectral library to facilitate the targeted protein identification, each sample from 103 1 6 7
tumors was pooled, fractionated to 48 fractions and subjected to DDA analysis. 1 6 8
The CV of SWATH-MS data was assessed using two QC approaches (Figure S1). For 1 6 9
the first method, peptides from HEK293 cells were analyzed in triplicate on three days 1 7 0
for a total of nine runs between the DDA data acquisition runs for spectral library 1 7 1 generation and the SWATH acquisition of the ovarian tumor data. The median CV for 1 7 2 3,855 quantified proteins was 8% and the mean total CV (reflecting the intra-and inter-1 7 3 al., 2017) ( Figure S1a) . For the second QC method, peptides from a control ovarian 1 7 5
tumor were analyzed using a DDA method on the same 5600+ TripleTOF mass 1 7 6
spectrometer that was used to acquire the SWATH data. These QC samples were run in 1 7 7
duplicate immediately prior to the SWATH acquisition of the ovarian tumor samples, and 1 7 8 again in duplicate 10 days later when half of the ovarian tumor sample data acquisition 1 7 9
runs were completed. These measurements resulted in a total CV of 7% for 781 1 8 0 quantified proteins ( Figure S1b) . For both QC strategies, the duration of the LC gradient 1 8 1 was identical to the gradient used for the SWATH analysis of the HGSOC samples. 1 8 2
Hence, the results from these QC strategies evaluated the analytical 1 8 3 measurement/technical variability of the SWATH-MS platform that was used to acquire 1 8 4
the data from the ovarian tumor proteins. 1 8 5 identified from the SWATH-MS data generally have slightly higher confidence. In 3 7 1 comparison, when we bootstrapped along the dimension of the number of quantified 3 7 2 proteins (Figure 4C , D) the ARI was refractory to the number of proteins included in the 3 7 3
clustering. The difference among the ARI values did not reach statistical significance 3 7 4 (i.e. the clusters were stable) when the number of quantified proteins was down-sampled 3 7 5
to 30% and 50% of the initial group of proteins in the iTRAQ DDA and SWATH-MS 3 7 6 datasets, respectively. Hence, the resulting clusters are largely insensitive to the number 3 7 7 of included proteins. 3 7 8 3 7 9
The sensitivity of molecular subtype clustering to the number of samples included in the 3 8 0 analysis has been shown previously (Levine and Domany, 2001; Monti et al., 2003) Nevertheless, in our SWATH-MS analysis, we were able to extract one robust HGSOC 3 9 1 subtype, which was characterized by the increased relative abundance of proteins with 3 9 2 extracellular matrix functions ( Figure S3A) . The robustness of this presumptive 3 9 3
Mesenchymal subtype as a function of sample number was demonstrated using different 3 9 4 P a g e 1 4 o f 4 0 subsets of samples in the SWATH-MS dataset using a Fisher's exact test ( Figure S3B ). 3 9 5
A fundamental premise of this stability analysis is that only the most robust information 3 9 6
can be reproducibly extracted from the data. The emergence of the Mesenchymal 3 9 7
phenotype as a robust subtype in the iTRAQ DDA and SWATH-MS data indicates that 3 9 8
biologically-relevant content can be robustly extracted from these 3 9 9
orthogonal/complementary analytical methods. The proteins characterizing the 4 0 0
Mesenchymal cluster in the SWATH data (86 proteins) and the iTRAQ DDA data ( also evidenced by the overlap among the Mesenchymal subtype tumors ( Figure 3A) . 4 0 7
These results suggest that the robustness of the clusters increases with increasing 4 0 8 quantification accuracy rather than by increasing number of quantified proteins. 4 0 9 4 1 0
To determine whether the same proteins from the iTRAQ DDA and SWATH-MS 4 1 1 datasets would be identified in a group comparison of Mesenchymal subtype samples 4 1 2
vs. the other samples, we used the sample subtype annotations from the Zhang et al.
iTRAQ DDA study (Zhang et al., 2016a) . The log 2 fold-changes of these proteins in the 4 1 4
iTRAQ DDA and SWATH-MS datasets were determined as well as the associated p-4 1 5 value ( Figure 6 ). Proteins with significantly increased or decreased abundance (fold-4 1 6
change cut-off: 1.3; p<0.05) are indicated in red or blue, respectively. The significantly 4 1 7 upregulated proteins ( Figure 6A and B, red dots) in these comparisons showed a high 4 1 8 overlap with the 84 common proteins from the ECM protein module ( Figure 6C) Also of note, the quantitative dimension of iTRAQ DDA is narrower than that of the 4 2 9
SWATH-MS data which influences the extent of similarity among the proteins quantified 4 3 0 by each method. 4 3 1 4 3 2
Since the proteomic subtypes other than the Mesenchymal subtype identified in the 4 3 3
CPTAC and TCGA studies could not be clearly distinguished by the classification 4 3 4
analyses of the data sets used in this study, we performed a similar differential 4 3 5 expression analysis on those groups using the 1,599 proteins that were quantified in the 4 3 6
iTRAQ DDA and SWATH-MS data sets ( Figure S5 ). As expected, the p-values of those 4 3 7
comparisons were considerably less significant than those resulting from the analyses of 4 3 8
the Mesenchymal subtype. The Differentiated and Stromal subtypes did not lead to any 4 3 9
conclusive results in these analyses based on the functional enrichment of the proteins 4 4 0
with increased or decreased relative abundances, while the Proliferative and 4 4 1
Immunoreactive subtypes were characterized by several differentially expressed 4 4 2 proteins with rather high p-values (low significance). The WGCNA analyses of the 4 4 3 respective differentially abundant proteins identified protein modules related to immune 4 4 4 response and gene expression and translation ( Figure S4) revealed several differentially expressed proteins (Figure 7A ). Because none of these 4 6 2
proteins could be directly linked to DNA repair mechanism-related functions, we used a 4 6 3 network propagation approach (Hofree et al., 2013) changes obtained from the group comparison approach were mapped on this network 4 6 8
and these signals were propagated over the network to identify signals accumulating 4 6 9
within a subnetwork. The top 5% (221 proteins) of the resulting positive and negative 4 7 0
scores were used for further investigation and functional enrichment. among the GO terms that were identified using the previously described network 4 7 5
propagation approach based on functional enrichment analysis. The respective sub-4 7 6
network contained proteins previously identified as belonging to the HRD-associated 4 7 7
protein network, including histone deacetylase 1 (HDAC1; Figure 7B ) and a histone-4 7 8
binding protein RBBP7 (Zhang et al., 2016a) ( Figure 7B ). HDAC1 and RBBP7 are 4 7 9
among the blue nodes representing chromosome organization proteins. organization network in our study and the results from in vitro studies indicating the 4 9 0
interaction of these proteins with PARP and BRCA1 support the well-known role of these 4 9 1
proteins in the control of homologous recombination during DNA repair. 4 9 2 4 9 3
In summary, the analysis of the SWATH data was not only able to provide confirmation 4 9 4
of some previously identified signatures from the iTRAQ DDA data in a larger untargeted 4 9 5 network approach, but it also provided important mechanistic insights into HRD-related 4 9 6 pathways as discovered by iTRAQ labeling and LC-MS/MS using DDA (Zhang et al., 4 9 7 2016a). HGSOC is among the cancer types that have been proteogenomically characterized by 5 0 4
CPTAC. The large-scale proteome analytical workflow employed by CPTAC uses 5 0 5
isobaric tagging, offline peptide fractionation and LC-MS/MS. This workflow is 5 0 6 considered a reference method for the comparison of tissue protein abundance across 5 0 7 large sample cohorts. However, recently, DIA proteomic methods exemplified by 5 0 8 SWATH-MS have been developed which are simpler, faster, cheaper, and consume less 5 0 9
sample than the reference method, but provide shallower proteome coverage. 5 1 0
Although HGSOC is the most common histological subtype of ovarian cancer, there is a 2016a) with varying numbers of molecular subtypes emerging from these analyses. 5 2 4
Functional genomic studies have identified various numbers of distinct HGSOC 5 2 5 molecular subtypes with clinical relevance and pathways that are responsible for growth 5 2 6
control in epithelial ovarian cancer (Cancer Genome Atlas Research, 2011; Tan et al., 5 2 7 2013). The discordance among these subtypes results from the varied sample sizes and 5 2 8
analytical criteria used to conduct these studies (Helland et al., 2011; Tothill et al., 2008 ;
Verhaak et al., 2013). Our current study provides orthogonal evidence of the proteomic 5 3 0
signatures of the HGSOC Mesenchymal subtype and the fidelity of the HGSOC 5 3 1
Mesenchymal subtype which is more sensitive to sample number compared to the 5 3 2 number of quantified proteins. This has implications for the design of future large-scale 5 3 3
clinical proteomic studies of cancer types where molecular subtyping is a predominant 5 3 4 goal. 5 3 5 5 3 6
In this study, we compared the results obtained by the reference large-scale DDA 5 3 7
proteomic method vs. SWATH-MS using aliquots of peptide samples generated for the 5 3 8
CPTAC HGSOC study (Zhang et al., 2016a) . The results indicate that iTRAQ DDA and 5 3 9
SWATH-MS confidently identified differentially expressed proteins in enriched pathways 5 4 0 associated with the Mesenchymal subtype of HGSOC tumors as evidenced by the: 1) 5 4 1 high degree of overlap of up-regulated extracellular matrix-related proteins (Figure 5A) , 5 4 2
2) strongly positive median correlation (ρ = 0.79) among the proteins comprising this 5 4 3 subtype from both proteomic workflows ( Figure 5B) , and 3) statistically significant 5 4 4 stability of this subtype in the context of the number of tumors included in the clustering 5 4 5 analysis ( Figure S3B) . The robustness of the Mesenchymal subtype with respect to 5 4 6 molecular subtype cluster stability could be a signature of the decreased survival of 5 4 7
patients whose tumor samples express this molecular signature compared to an 5 4 8
Immunoreactive signature. A study conducted using a cohort of 174 HGSOC patients The notion of discrete HGSOC subtypes that are mutually exclusive is not universally dimensional approach to subtyping where molecular subtypes lie on a spectrum with 5 6 1 partly overlapping causes (Konecny et al., 2014) . Additional large-scale clinical 5 6 2
proteomic studies of HGSOC tumors that are designed to address issues related to 5 6 3
tumor heterogeneity would be beneficial in enhancing the resolution of molecular 5 6 4
subtyping. 5 6 5 5 6 6
Our SWATH-MS analysis confirmed the proteomic signature of HRD established by 5 6 7
iTRAQ DDA analysis wherein a sub-network of BRCA1-or BRCA2-related proteins 5 6 8
displayed co-expression patterns differentiating HRD from non-HRD patients (Zhang et  5  6  9 al., 2016a). Many of the proteins in these identified modules have roles in histone tissue biopsies from patients who receive PARP inhibitor treatment could be beneficial in 5 7 5
further elucidating the molecular mechanisms that are implicated in HRD. 5 7 6 5 7 7
One of the strengths of the iTRAQ DDA workflow is the ability to achieve deep proteome 5 7 8
coverage which exceeds that of the SWATH workflow by almost 3-fold. A total of 8,597 5 7 9
proteins were quantified by iTRAQ DDA compared to 2,914 proteins by SWATH-MS. 5 8 0
These numbers represent the aggregate numbers of quantified proteins. However, after 5 8 1
employing filtering strategies to restrict the data to only the proteins that were quantified 5 8 2 across all 103 tumors for each workflow, these numbers decreased to 4,363 and 1,659,
respectively. The group of 1,599 proteins that were quantified by both proteomic 5 8 4
workflows was used to compare the performance of iTRAQ DDA and SWATH-MS. 5 8 5 5 8 6
In addition to their analytical performance, there are also considerable differences in the 5 8 7
resource characteristics of iTRAQ DDA and SWATH-MS, including sample requirement, 5 8 8
sample throughput and cost. Hence, it is clear that iTRAQ DDA for comprehensive 5 8 9
proteome profiling is a substantially more resource-intense workflow compared to 5 9 0 SWATH-MS. 5 9 1 5 9 2
Based on the concordance between the iTRAQ DDA and SWATH-MS results that we 5 9 3
have shown in this study, SWATH-MS, which is considerably less resource-intense than 5 9 4
iTRAQ DDA, can be reliably deployed in the proteomic analysis of clinical specimens. 5 9 5
The clinical utility of future large-scale translational proteomic studies, regardless of the 5 9 6
employed analytical methodology, can be strengthened by the use of large sample 5 9 7
cohorts that have undergone comprehensive pathology review. 5 9 8 5 9 9
Although our study was focused on the performance of SWATH-MS, other DIA methods 6 0 0 are currently available. Our SWATH-MS analysis was conducted using a 5600 + Triple-6 0 1 TOF mass spectrometer; however, a newer generation of this mass spectrometer 6 0 2 platform exists with an increased linear dynamic range and enhanced detection system, 6 0 3 which could result in improved instrument performance with respect to the number of 6 0 4 quantifiable proteins per analytical run. A recent DIA study conducted by Bruderer et al. 6 0 5
using a quadrupole ultra-high field Orbitrap mass spectrometer resulted in the 6 0 6
identification of more than 6,000 proteins in human cell lines and more than 7,000 6 0 7
proteins in mouse tissues (Bruderer et al., 2017) . Of note, the use of isobaric chemical 6 0 8
labeling strategies, including 10-and 11-plex tandem mass tags (TMT), has greatly 6 0 9
facilitated the multiplexing capabilities of large-scale clinical proteomic studies resulting 6 1 0
in the reproducible quantification of >10,000 proteins ( As expected, the development of new analytical instruments and methods often enables 6 2 0
an expanded breadth and/or depth of analytical measurement. After the performance of 6 2 1 these instruments and methods has been optimized and validated, the short-comings of 6 2 2 previously existing methods become evident. It is as-yet unknown whether SWATH-MS 6 2 3
and other DIA proteomic methods will have an increased prevalence in clinical 6 2 4
proteomic analyses. However, our current study provides compelling orthogonal 6 2 5
evidence that SWATH-MS elucidates some of the common biological signatures of the 6 2 6
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Figure legends
Cancer Genome Atlas (TCGA) were processed for proteomic analysis using an iTRAQ 6 5 6
DDA method wherein the samples were subjected to fractionation prior to data 6 5 7
acquisition and also using a SWATH-MS method without fractionation prior to analysis. 6 5 8
The data processing and bioinformatics pipeline enabled differential expression analysis 6 5 9
and tumor subtype classification comparison. Proliferative; Green -Immunoreactive; Yellow -Stromal. b) Subtype classification 6 7 4 agreement among the genomic and proteomic data assessed by the Adjusted Rand 6 7 5
Index (ARI). to the ECM module in the iTRAQ DDA data and the SWATH-MS data. Tumor samples The tumor specimens were obtained through The Cancer Genome 7 1 7
Atlas (TCGA) Biospecimen Core Resource, and they were previously genomically 7 1 8 characterized (Cancer Genome Atlas Research, 2011). As previously described (Zhang 7 1 9 et al., 2016a), the biospecimens were obtained from newly diagnosed patients with 7 2 0 ovarian serous adenocarcinoma who were undergoing surgical resection and did not 7 2 1 receive prior treatment, including chemotherapy or radiotherapy, for their disease. 7 2 2
Frozen tissue specimens were extracted and used for subsequent proteomic analysis. tissue specimen was sonicated in 1.5mL of 8M urea, 0.8M NH 4 HCO 3 , pH 8.0. Protein 7 2 8
concentration was determined using a BCA assay (Thermo Fisher Scientific). Protein 7 2 9
disulfide bonds were reduced with 10mM tris (2-carboxyethyl) phosphine (TCEP) for 1h 7 3 0 at 37°C, followed by alkylation with 12mM iodoacetamide for 1h at RT in the dark. After 7 3 1 dilution 1:4 with deionized water, proteins were digested with sequencing-grade modified 7 3 2 trypsin (Promega, Madison, WI) (1:50 enzyme:protein, weight/weight) for 12h at 37°C. 7 3 3
This was followed by the addition of an aliquot of the same amount of trypsin and 7 3 4
incubation overnight at 37°C. The digested samples were acidified with 10% 7 3 5
trifluoroacetic acid (TFA) to pH<3, de-salted using strong cation exchange and C18 7 3 6
solid-phase extraction (SPE) columns (Waters, Milford, MA) and dried using a Speed-7 3 7
Vac. 7 3 8 7 3 9
Shotgun proteomics using iTRAQ data-dependent acquisition (DDA) Relative 7 4 0 quantitative proteomic analysis was conducted using 4-plex isobaric tags for relative and 7 4 1 absolute quantitation (iTRAQ) reagents (Sciex) as previously described (Zhang et al., 7 4 2 2016a). Peptides (500µg) were dissolved in 150µL of 0.5M triethylammonium 7 4 3 bicarbonate, pH 8.5 and combined with 5U of 4-plex iTRAQ reagent dissolved in ethanol 7 4 4
followed by a 2h incubation at RT, quenching with 10% TFA, and de-salting using C18 7 4 5 SPE columns. iTRAQ channel 114 was used to label the reference sample which was 7 4 6 created by pooling an aliquot from each individual tumor sample. Offline basic reversed 7 4 7 phase liquid chromatography (bRPLC) was conducted using a Zorbax extend 4.6 x 7 4 8 100mm C-18 column (Agilent) and an Agilent 1220 Infinity HPLC system to reduce the 7 4 9
sample complexity prior to mass spectrometry analysis. A total of 96 fractions were 7 5 0 collected and concatenated into 24 fractions. The fractions were dried in a Speed-Vac 7 5 1 and stored at -80°C until analysis by LC-MS/MS using an LTQ Orbitrap Velos mass 7 5 2 spectrometer (Thermo Scientific). Peptides were loaded onto a 2cm guard column 7 5 3 (Thermo Scientific) and separated on a 75µm x 15cm Acclaim PepMap100 column 7 5 4 (Thermo Scientific) using a Dionex Ultimate 3000 RSLC nano chromatography system 7 5 5
(Thermo Scientific were collected from 400-1800 m/z at a resolution of 30,000 followed by data-dependent 7 5 9
MS/MS (7,500 resolution) of the ten most abundant ions. Charge-state screening was 7 6 0 enabled to prevent the acquisition of MS/MS spectra for ions with unassigned or single 7 6 1 charges. Dynamic exclusion (40s duration) was enabled to minimize the repeated 7 6 2 acquisition of previously acquired MS/MS spectra. 7 6 3 7 6 4
Proteomic analysis using SWATH mass spectrometry SWATH-MS measurements 7 6 5
were conducted at the Johns Hopkins University using a Sciex 5600 + TripleTOF mass 7 6 6
spectrometer interfaced with an Eksigent ekspert nanoLC 425 cHiPLC system. Peptides 7 6 7
(1µg) were loaded onto a 6mm x 200µm ChromXP C18-CL 3µm, 120Å trap column 7 6 8
followed by separation on a 75µm x 15cm ChromXP C18-CL 3µm, 120Å Nano cHiPLC 7 6 9 column using a 120min method (90min gradient from 3-35% B -0.1% formic acid in 7 7 0 acetonitrile) at a flow rate of 300 nL/min. To create the spectral library for the SWATH-7 7 1 MS data analysis, each sample was run individually (1µg peptides per injection) using a 7 7 2 data-dependent data acquisition (DDA) method wherein MS spectra were acquired 7 7 3 across a range of 400-1800 m/z followed by the acquisition of MS/MS spectra of the top 7 7 4 30 most intense precursor ions with a charge state of z=2-5. The spectral library was 7 7 5 also comprised of mass spectrometry data acquired from a fractionated (48 fractions) 7 7 6
pool of peptides from all 103 tumors. Each of the 48 fractions from the pooled sample 7 7 7
was analyzed using the same DDA method described above. SWATH data of the 7 7 8
individual tumors were acquired using a variable window strategy wherein the sizes of 7 7 9
the precursor ion selection windows were inversely related to m/z density. The average 7 8 0 window width for precursor ion selection was 12 m/z with a range of 6-25 m/z. The 7 8 1 collision energy was optimized for each window according to the calculation for a charge 7 8 2 2+ ion centered in the window with a spread of 5 eV. The MS accumulation time was 7 8 3 250ms and the MS/MS accumulation time for fragment ions accumulated in high 7 8 4 sensitivity mode was 50ms, resulting in a total duty cycle of approximately 3.5s. To 7 8 5
assess the analytical precision of the proteomics measurements, peptides from trypsin-7 8 6 digested HEK293 cell proteins were analyzed via SWATH-MS in triplicate immediately 7 8 7
prior to the SWATH-MS analysis of the 103 individual tumor samples. Additionally, an 7 8 8 ovarian cancer tumor sample separate from the TCGA collection was used as a QC 7 8 9
sample. This specimen was analyzed using the DDA method described above in 7 9 0 P a g e 2 8 o f 4 0 duplicate prior to the SWATH-MS analysis of the 103 individual tumor samples and 10 7 9 1 days later in duplicate mid-way through the analysis of the individual tumor samples. 7 9 2
Instrument performance was assessed daily by monitoring the peak area of 5 peptides 7 9 3 from a trypsin-digested E. coli ß-Galactosidase LC-MS standard that was injected every 7 9 4 day a sample was run on the mass spectrometer. 7 9 5 7 9 6 iTRAQ DDA data processing iTRAQ DDA data from the Johns Hopkins CPTAC center 7 9 7
was analyzed by the Common Data Analysis Pipeline (CDAP) and downloaded from the 7 9 8
NCI CPTAC Data Portal (https://cptac-data-portal.georgetown.edu/cptac/s/S026); mass 7 9 9 spectrometry site: Johns Hopkins University (Edwards et al., 2015; Ellis et al., 2013) . 8 0 0
Values obtained from proteotypic peptides were chosen for further analysis. The protein 8 0 1
matrix contained 8597 proteins. The protein matrix was filtered for proteins without 8 0 2
missing values (4363 proteins). PSM files were additionally downloaded from the 8 0 3
CPTAC Data Portal and processed following the CDAP to the peptide level data in order 8 0 4
to investigate peptide variability. 8 0 5 8 0 6
SWATH-MS data processing Raw mass spectrometry measurements obtained from 8 0 7
the TripleTOF 5600 + in DDA and SWATH mode were converted to mzXML file format 8 0 8
using OpenSWATH results were annotated and formatted using the R package SWATH2stats 8 2 7
(v.1.0.3) (Blattmann et al., 2016) prior to quantile normalization (preprocessCore 8 2 8
v.1.32.0) (Bolstad, 2017) and batch-wise mean-centering batch correction of known 8 2 9
sample preparation batches. Fragment-level data was then fed into mapDIA (v.3.0.2) 8 3 0
( Teo et al., 2015) in order to filter for outliers and proteins with at least 3 fragments per 8 3 1
peptide and 2 peptides per protein. The 3 most intense fragments per peptide were 8 3 2
summed and the resulting peptide intensities were divided by the mean peptide intensity 8 3 3
(as an internal reference) over all runs to obtain a similar data structure as in iTRAQ 8 3 4
DDA. Peptide ratios were averaged per protein. A total of 2914 proteins were quantified 8 3 5
in this manner across all 103 samples. 8 3 6 8 3 7
An additional filtering and imputation step was conducted to mitigate the missing values 8 3 8
in the SWATH data. Figure S2B shows the number of missing values in the SWATH 8 3 9
data and their occurrence dependent on the protein abundance represented by log 2 8 4 0
intensity (Figure S2C) . As expected, there is an inverse relationship between protein 8 4 1
abundance and missing values. Missing values in low abundance proteins are more 8 4 2 likely to occur due to technical reasons, while missing values amongst high abundance 8 4 3
proteins potentially have biological significance which might be important for further 8 4 4
analysis. We therefore filtered the protein matrix based on the occurrence of abundance-8 4 5
dependent missing values. We confined the number of missing values using a stricter 8 4 6
threshold for low abundance proteins than high abundance proteins according to the 8 4 7
following rules: no missing values were allowed for the lowest abundant 10% of 8 4 8
proteins, 10% missing values were allowed for the next 10% abundant proteins and so 8 4 9
on until 90% missing values were allowed for the highest abundant proteins. A total of 8 5 0
1659 proteins remained passed these filtering steps. The missing values from those 8 5 1
proteins were filled using an imputation method based on what is used by Perseus representing values within the noise. 8 5 5 8 5 6
QUANTIFICATION AND STATISTICAL ANALYSIS 8 5 7
Bioinformatics pipeline 8 5 8
Bioinformatic analyses were performed in R (v.3.2.2 "Fire Safety"). 8 5 9
Technical evaluation. A total of 1599 proteins common to the iTRAQ DDA and SWATH 8 6 0
data sets were evaluated for their correlation and variability (Figure 2) . 2012) (Figure S4) . The resulting molecular classifications were compared based on 8 7 5
their similarity using the Adjusted Rand Index (ARI), a measure for classification 8 7 6 similarity, implemented within the R package mclust previously used. The heat map 8 7 7
displayed in Figure S3A was generated based on SWATH z-scores using pheatmap 8 7 8
(v.1.0.8) (Kolde, 2015) . The stability of the classification results was evaluated by 8 7 9
bootstrapping. Different fractions of samples or proteins were drawn 100 times and 8 8 0
classified using mclust with default settings, and the similarity to the molecular 8 8 1 classification of the full data set was compared with the ARI (Figure 4) . bootstrapping approach by drawing a fraction of samples 100 times (Figure S3B) . 8 8 6
Group comparison of the original classes from CPTAC (Zhang et al., 2016a) were 8 8 7
obtained by a student's t-test (Figure 6 and S4) . As an input network the STRING database for human (Taxon 9606 v.10.5) was 8 9 6
downloaded and filtered for interactions with experimental evidence and a score >800. 8 9 7
The top 5% of negative and positive scores were used for further investigation of 8 9 8
functional enrichment of Gene Ontology using the STRING database (STRING-db.org 8 9 9
v.10.5 accessed on 2018/03/14). 9 0 0 9 0 1 DATA AND SOFTWARE AVAILABILITY 9 0 2
Mass spectrometry data 9 0 3
All the raw data from SWATH-MS measurements, along with the input spectral library 9 0 4
and OpenSWATH results can be freely downloaded from the ProteomeXchange 9 0 5
Consortium ( portal.georgetown.edu/cptac/s/S026); mass spectrometry site: Johns Hopkins 9 1 0
University. Other data are available from the corresponding authors upon request. 9 1 1 9 1 2
Programming codes 9 1 3
All code used for the downstream bioinformatics pipeline can be obtained from the 9 1 4
github repository (bfriedrichgrube/OC_CPTAC_iTRAQ_SWATH). analyzed via SWATH (n=3 technical replicates per day for 3 days; total = 9 technical 9 2 4
replicates) prior to the analysis of the ovarian tumors. Median total CV=15%; 3,855 9 2 5 quantified proteins. b) Distribution of quantified protein CVs from a control ovarian tumor 9 2 6
analyzed in duplicate via DDA prior to and mid-way through the ovarian tumor SWATH 9 2 7
analyses (n=4 technical replicates). Median total CV=7%; 781 quantified proteins. association is denoted by colored dots indicating the q-value, and the number of proteins 9 4 9
mapped to a given ontology as a proportion of the total number of proteins in the module 9 5 0 (GeneRatio) is indicated by the size of the dot. The WGCNA-derived protein modules for 9 5 1
the iTRAQ DDA data are as follows: magenta -gene expression; black -immune 9 5 2 response; purple -transcription; tan -erythrocyte and platelet; magenta -cytokine 9 5 3 signaling; red -ECM interaction; gray -metabolism. The WGCNA-derived protein 9 5 4 modules for the SWATH data are as follows: green -immune response; turquoise -9 5 5 gene expression; black -ECM interaction; red -complement cascade; gray -9 5 6 metabolism. 9 5 7 9 5 8 Figure S5 . Differential relative protein abundance analysis of proteins in the 9 5 9
Differentiated, Immunoreactive, Proliferative and Stromal subtype tumors from the 9 6 0 iTRAQ DDA and SWATH-MS datasets. Up-regulated proteins are indicated in red and 9 6 1 the down-regulated proteins are indicated in blue. The log 2 fold-change cut-off was 1.3 9 6 2 and the significance cut-off was set at p<0.05. Yang, E.S., Alvarez, R.D., Huh, W. K., et al. (2018) . Molecular Response to Neoadjuvant Chemotherapy 9 7 0 in High-Grade Serous Ovarian Carcinoma. Mol Cancer Res.
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